4 active not recruiting, 3 recruiting, 2 withdrawn, 1 completed. 7 Phase 1, 2 Early Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 2, Recruiting 2, Withdrawn 2, Completed 1 |
| Early Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Stage IVA Fallopian Tube Cancer AJCC v8: new trials by email Literature Review of Stage IVA Fallopian Tube Cancer AJCC v8 trials Research Report on Stage IVA Fallopian Tube Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs - Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8 | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2023-12-15 | 2023-11-22 | |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Quality-of-Life Assessment, Radiation Therapy, Talazoparib - Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-26 | 2026-03-11 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
Fallopian Tube Neoplasms (10) · Ovarian Neoplasms (10) · Endometrial Neoplasms (3) · Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Endometrioid (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Peritoneal Neoplasms (1) · Sarcoma, Synovial (1) · Vaginal Neoplasms (1)
Adnexal Diseases (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Fallopian Tube Diseases (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Gonadal Disorders (10) · Neoplasms (10) · Neoplasms by Site (10) · Ovarian Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10)
Drug Therapy (2) · Taxes (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Cytoreduction Surgical Procedures (1) · Decitabine (1) · Fulvestrant (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Injections (1) · Ipilimumab (1)
M.D. Anderson Cancer Center (5) · Roswell Park Cancer Institute (2) · Ohio State University Comprehensive Cancer Center (1) · Pamela Munster (1) · Precigen, Inc (1)
United States (9) · Canada (1) · Italy (1) · Mexico (1) · Netherlands (1)
Amir A Jazaeri (1) · Amy R. Lankford, PhD (1) · Apostolia M Tsimberidou (1) · Emese Zsiros, MD, PhD (1) · Floor Backes, MD (1) · Jose A Rauh-Hain (1) · Lilie L Lin (1) · Pamela N Munster, MD (1) · Philip McCarthy, MD (1) · Shannon N Westin (1)
P30CA016056 (1), P50CA159981 (1), R01CA164333 (1)